Wockhardt makes breakthrough in pneumonia treatment with Nafithromycin WCK 4873
Wockhardt is proud to announce the successful completion of its pivotal Phase 3 pneumonia study involving the macrolide antibiotic Nafithromycin WCK 4873. This significant achievement ... Read More